Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor

(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news